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Involuntary treatment of schizophrenia
patients 2004–2010 in Denmark
Andersen TH, Kappers D, Sneider B, Uggerby P, Nielsen J.
Involuntary treatment of schizophrenia patients 2004-2010 in
Denmark.
Objective: Treatment of schizophrenia is frequently complicated by
patients’ ambivalence and lack of insight into the disease, occasionally
warranting involuntary treatment. This study aims to describe
involuntary treatment in Danish schizophrenia patients.
Method: Patients diagnosed with a lifetime ICD-10 F20
schizophrenia diagnosis and alive in the period 2004–2010 were
identified in the Danish Psychiatric Central Research Register, and
data were linked to The Registry of Coercive Measures in
Psychiatric Treatment.
Results: Within the study period, a total of 18 599 admitted patients
were identified, 3078 of which underwent involuntary treatment. The
incidence rate for any involuntary treatment was 2.1 per in-patient
year and 1.7 and 0.3 per in-patient year for rapid tranquilization
and involuntary treatments, respectively. Somatic diseases comprised
34.5% of all involuntary treatments. Psychotropics comprised 56.9%
with antipsychotics as the most common drug class (99.5%).
Olanzapine was the most commonly used antipsychotic drug
(33.2%). Treatment with depot injection and clozapine comprised
only 13% and 4.8% of the antipsychotics used, respectively.
Electroconvulsive therapy comprised 4.8% of all involuntary
treatment.
Conclusion: Involuntary treatment involved a wide range of somatic
treatment. Antipsychotic medicine was the most common psychotropic
used. Involuntary treatment with depot antipsychotics and clozapine
were rare.
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Significant outcomes
• One-third of all involuntary treatments included somatic treatment or procedures, with treatment
of acetaminophen overdose and compulsory feeding as the most common.
• Schizophrenia patients only rarely are subjected to involuntary treatment with clozapine or depot
antipsychotics.
• Patients subjected to involuntary treatment had a history of more psychiatric admissions and an
earlier onset of schizophrenia.
Limitations
• The mental health acts differ between countries, and therefore, the conclusions of this study may not
be generalizable.
• Description of symptoms or indication for the involuntary treatment was not available.
• Data from The Registry of Coercive Measures in Psychiatric Treatment were only available from
2004 until end of 2010.
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Introduction
Schizophrenia is a debilitating and social disrup-
tive disease affecting 0.5–1.0% of the population
and often it have a chronic course with 10% being
institutionalized (1–3). Besides being tormented by
psychotic symptoms, schizophrenia patients more
often live alone (4) and are having comorbid
substance misuse (5).
In addition schizophrenia is a life-shortening
disease with up to 25 years reduction of lifespan
compared with the background population (6).
Lifetime risk for committing suicide is approxi-
mately 5% (7). Lifestyle related conditions such as
inactivity, obesity, smoking contribute significantly
to increased mortality causing increased risk of
cardiovascular diseases (8). Studies also have
shown that schizophrenia patients are less likely to
receive the proper somatic treatment (9).
Antipsychotics are considered the cornerstone
in treatment, but patients’ ambivalence and lack
of insight often tend to complicate treatment (10,
11). Up to 50% of the patients are non-compli-
ant to the medication (12). Lack of insight may
cause refusal of receiving antipsychotic medica-
tions, leading to failure of initiation or continua-
tion of therapy and worsening of the outcome
(13). Involuntary treatment may thus be war-
ranted to avert risk of suicide, treating a life-
threatening medical condition, aggressiveness or
to facilitate insight into the disease, to conse-
quently accept the necessity of treatment. Espe-
cially, substance abuse, lack of insight and male
sex seems to increase the risk of involuntary
admission (14–16).
The use of involuntary treatment in psychiatry is
highly controversial and has been extensively
debated (15, 17–19). Essential of this discussion is
the issue of loss of autonomy versus necessity of
treatment both from society and patient’s health
points of view.
Furthermore, involuntary treatment may keep
patients from seeking proper treatment later on
(20).
In Denmark involuntary treatment is governed
by the Mental Health Act. All involuntary inter-
ventions are registered on specified coercive proto-
cols and reported electronically to a nation-wide
register. Involuntary treatments are restricted to
inpatient status. Continuation during outpatient
status thus is not allowed, and consequently effec-
tiveness of the involuntary treatment is pending on
the patients gaining insight into their disease dur-
ing treatment, thereby possibly gaining a more
positive attitude and larger acceptance of the
needed medications.
In Denmark, involuntary treatment is divided
in two different groups and registered on two dif-
ferent coercive protocols. Involuntary treatment
involving treatment of psychosis or a life-threat-
ening medical condition (Coercive Protocol 2)
compared with rapid tranquilization used for
treating severe agitation in the emergency settings
(Coercive Protocol 3). The Coercive Protocol is
the piece of paper where the psychiatrist docu-
ments the involuntary measure. Each type of
involuntary measure has a specific protocol
reflecting the different clauses in the Mental
Health Act. Measures governed by Coercive Pro-
tocol 3 can only be used once per protocol,
whereas involuntary treatment by Coercive
Protocol 2 makes it possible to apply the treat-
ment once or several times per day until the con-
dition has been cured or the patient accepts the
treatment.
Rapid tranquilization can be applied by any
doctor in the psychiatric ward were as involuntary
treatment (Coercive Protocol 2) warrants accept
from a psychiatric consultant. Only well-known
drugs are permitted, and dosage should be within
the recommended dose range. The use of involun-
tary treatment should always be proportionate to
the goal pursued. Whenever possible, minor steps
should be taken and accordingly involuntary treat-
ment is divided in two measures: The main and the
subsidiary treatment. The main treatment is less
intrusive for the patient and usually is an orally
administered drug, that is, tablets, orally disinte-
grating tablets or draught. If completing the main
treatment is not possible, for example the patient
refuses to take the tablets, the subsidiary treatment
is used, usually an injectable drug. Long-acting
depot antipsychotics only are allowed under cer-
tain circumstances, such as recurring discontinua-
tion of treatment with relapse.
In life-threatening conditions the Mental Health
Act permits specific involuntary measures, such as
electroconvulsive therapy (ECT) or specific and
necessary treatment of physical disease. Treat-
ments of life-threatening physical disease warrant
accept from both a psychiatric and a somatic con-
sultant.
All patients subjected to involuntary measures
are offered the assistance of a patient counsellor,
through which patients may complain, and for the
exception of life-threatening conditions, or severe
violence, treatment is postponed until approved by
the Patients’ Complaints Board. Rapid tranquiliza-
tion does not warrant approval by Patients’
Complaints Board but patients can complain
afterwards. Obtaining sufficient treatment in
schizophrenia and avoiding relapse is considered
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important and may even improve the long-term
outcome of the disease (2, 21). Little, however, is
known about involuntary treatment.
Aims of the study
This study aims to enlighten current practice by
analysing types of treatment, the kind of drugs
used, as well as their dosage.
Material and methods
Sample and registers
The population consisted of patients alive in the
period 2004–2010 with a lifetime diagnosis of
Schizophrenia (ICD10 F20.0–9). Patients were
identified in the Danish Psychiatric Central
Research Register (DPCRR) (22). The DPCRR
contains information of all psychiatric admissions
from 1969 and outpatient contacts from 1995 and
onwards. The DPCRR has extensively been used
for research and the validity is high (2, 23). Data
were linked to The Registry of Coercive Measures
in Psychiatric Treatment using the unique personal
ID number. The reporting is based on paper proto-
cols until January 01 2005; afterwards, the reporting
is done electronically from the hospitals. The regis-
try contains information on all involuntary mea-
sures from all psychiatric hospitals in Denmark.
Only involuntary measures initiated during the
study period where included. The National Health
Service, Statistics Denmark and The Danish Data
Protection Agency approved the use of the data for
the study. Data were accessed anonymously
through a remote access to Statistics Denmark.
Outcome variables
This study includes two measures, involuntary
treatment of psychosis or medical condition (Coer-
cive Protocol 2) and rapid tranquilization (Coer-
cive Protocol 3). Drugs used for rapid
tranquilization were not specified on the protocol,
and for this reason only incidence rates could be
reported. Coercive Protocol 2 includes a text string
named ‘type and volume’. This text string was
deciphered into following variables: drug name,
start and end dose. All of these variables were
coded for both the main and the subsidiary
treatment. Psychotropics were coded by their
Anatomical Therapeutic Class (ATC) code, and
classes of psychotropics were defined as: antipsy-
chotics (N05A except N05AN01), antidepressants
(N06A), stimulants (N06B), benzodiazepines
(N03AE01 & N05BA), anticholinergic (N04A) and
mood stabilizers including lithium (N05AN01),
valproate (N03AG01), carbamazepine (N03AF01)
and lamotrigine (N03AX09).
The recommended dose range for each antipsy-
chotic drug was identified from the Danish sum-
mary of product characteristics (SPC), which was
obtained from either the Danish Medicines Agency
or European Medicines Agency. This was carried
out to calculate the number of patients and per-
centage of those receiving higher dosages than the
recommended range. Treatment including more
than one psychotropic was registered as polyphar-
macy, and each drug was included in the table.
Thus, the total number of drugs used exceeds the
number of involuntary treatments.
For patients having more than one involuntary
treatment, demographic data were registered dur-
ing their first period. Demographics and treatment
history were compared with patients not undergo-
ing involuntary treatment or rapid tranquilization
within the study period. For these controls, the
index time was set to their first psychiatric admis-
sion within the study period, to calculate (e.g.)
numbers of previous admissions and duration of
illness.
For other analyses than demographics, all epi-
sodes of involuntary treatment within the study
period were used in the analysis. Types of somatic
treatment were manually categorized in relevant
types of treatment.
Statistics
Statistical calculations were taken with STATA
version 12.0. Mean values were compared, using
unpaired student t-test. In case of non-normal dis-
tribution, the variables were transformed. Binary
variables were compared by chi-squared test.
Only double-sided test results were reported and
only P-values less than 0.05 were considered statis-
tically significant. Observation time for incidence
rate analysis were defined as from 0 to 1st of Janu-
ary 2004 or onset of schizophrenia if later, until
death or end of register 31 December 2010 which-
ever came first. Incidence rates were reported for
multiple episodes, that is patients with more than
one episode had all episodes included in the
analysis.
Results
Descriptive analysis
During the study period, a total of 34 898 people
had a lifetime diagnosis of schizophrenia, and
18 599 had at least one psychiatric admission
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within the study period and were considered the
study population.
In total 3078 patients (16.5%) of the admitted
patients underwent involuntary treatment or rapid
tranquilization. Total number of registrations of
rapid tranquilization was 16 364 by 2574 patients
(median 2.0 treatments per person 25–75 percen-
tiles 1–6; range, 1–270). Corresponding figure of
involuntary treatment was 3151 treatments by
1384 patients (median 1 treatment per person,
25–75 percentiles 1–2, range 1–35). Eight hundred
and eighty patients had both at least one episode
of rapid tranquilization and one involuntary
treatment.
The total observation time was 195 929 patient
years with 9363 in-patient years. The incidence rate
for any involuntary treatment was 2.1 per in-
patient year and 1.7 and 0.3 per in-patient year for
rapid tranquilization and involuntary treatments,
respectively. Demographics of patients subjected
to any involuntary treatment vs. admitted patients
not receiving involuntary treatment are shown in
Table 1. Patients undergoing involuntary treat-
ment were younger, with earlier onset of both
schizophrenia and any psychiatric disease, and
more prior psychiatric admissions compared with
admitted patients not receiving involuntary treat-
ment as shown in Table 1.
Psychotropics comprised 56.9% of all involun-
tary treatments as shown in Table 2. Mean num-
ber of times the medication was administered
involuntarily was 27 (25–75 percentiles 8–61,
range, 0–822) times. Electroconvulsive therapy, of
which 25% was given ‘en bloc’ (daily treatment for
three consecutive days, bilaterally), comprised
4.8% of all involuntary treatments.
In 18% per cent of the protocols, data were
blank or insufficiently registered, meaning the
description in the protocol was not explicit enough
for anyone else but the physician himself to
decipher what treatment to be administered.
Involuntary psychopharmacological treatment
Antipsychotics comprised 99.5% of all involuntary
treatments involving psychotropics as shown in
Table 2. Olanzapine was the most commonly
administered antipsychotic drug (33.2%) (cf.
table 3). Of the 1792 involuntary treatments, 163
(9.1%) treatments included polypharmacy. Anti-
psychotic polypharmacy comprised 46 (28.2%) of
the total number of treatments involving polyphar-
macy. Other combinations of polypharmacy were
antipsychotic + anticholinergic 87 (53.4%), anti-
psychotic + benzodiazepines 38 (23.3%) and
antipsychotic + moodstabilizer 10 (6.1%).
In total 203 involuntary treatments (13.0%)
involved long-acting depot injections
Table 1. Demographics of admitted schizophrenia patients
No involuntary
treatment
(N = 15 521)
Any involuntary
treatment
(N = 3078) P-value
Male sex 8 967 (57.8%) 1777 (57.7%) 0.96
Age (years) 38.7 (SD = 15.5) 34.4 (SD = 11.7) <0.001
Age at first psychiatric
contact (years)
28.1 (SD = 11.0) 24.4 (SD = 8.3) <0.001
Age at onset of
schizophrenia (years)
33.0 (SD = 12.7) 29.0 (SD = 13.1) <0.001
Duration of psychiatric
illness (years)
12.9 (SD = 11.6) 12.5 (SD = 9.9) 0.038
Duration of
schizophrenia (years)
10.6 (SD = 10.6) 9.3 (SD = 8.6) <0.001
Number of previous
psychiatric admissions
(#, 25–75 percentiles)
4 (0–11) 7 (2–17) <0.001
Percentage of
hospitalization during
course of schizophrenia
(percentage, 25–75
percentiles)
5.6 (1.2–15.2) 10.0 (2.6–23.7) <0.001
Time from hospitalization to
decision on involuntary
treatment (days)
– 6.1 (SD = 20.0) –
Table 2. Types of involuntary treatment (Coercive Protocol 2).
Total Subtotal
Total 3151 (100.0%)
Any kind of ECT 152 (4.8%)
ECT 114 (75.0%)
ECT-en bloc 38 (25.0%)
Somatic treatment/procedures 640 (20.3%)
Acetaminophen overdose 151 (23.6%)
Antibiotics 29 (4.5%)
Anticoagulant therapy 30 (4.7%)
Blood sampling 37 (5.8%)
Blood transfusion 6 (0.9%)
Compulsory Feeding 109 (17.0%)
Diagnostic imaging 6 (0.9%)
Fluid replacement therapy 46 (7.2%)
Gastroscopy 8 (1.3%)
Insulin 24 (3.8%)
Surgical 46 (7.2%)
Treatment of withdrawal symptoms 9 (1.4%)
Other overdose 63 (9.8%)
Other/unspecified 76 (11.9%)
Psychotropics* 1792 (56.9%)
Antipsychotics 1783 (99.5%)
Antidepressants 9 (0.5%)
Mood stabilizers 11 (0.6%)
Benzodiazepines 38 (2.1%)
Anticholinergic 87 (4.9%)
Stimulants 0 (0.0%)
Unsatisfied filled out 567 (18.0%)
Blank 512 (90.3%)
Lack of information 55 (9.7%)
*The total percentage of the individual drug groups is higher than 100% because
some patients are treated with polypharmacy.
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(zuclopenthixol acetate not included). Especially
for olanzapine, quetiapine and ziprasidone large
portion of the oral treatment exceeded the
maximum recommended dose.
Pharmaceutical form
Solid tablets were most commonly administered
for main treatment, whereas short-acting injection
was the most common for the subsidiary treatment
(cf. Table 4.) Other orally administered pharma-
ceutical forms were also commonly administered
for the main treatment, that is orally disintegrating
tablets (22.2%) and draught (16.5%). Gastric
tubes were used in less than 1% of cases for both
main and subsidiary treatment and were mainly
used for clozapine treatment.
Discussion
This is the first study to ever investigate involun-
tary treatment of schizophrenia patients in Den-
mark. Treatment with psychotropics comprised
only 56.9% of the total number of involuntary
treatments. Somatic involuntary measures thus
comprised 20.3%, overdose being the most fre-
quent somatic condition. Somatic involuntary
treatment included a wide variety of conditions
from minor interventions, for example rehydra-
tion, or more severe interventions such as amputa-
tion of limbs.
The average age of patients who have been
undergoing involuntary treatment was mid-thirties
as found in a previous study by Jarrett (11).
Although more males underwent involuntary
treatment, their relative proportion was similar to
admitted patients not undergoing involuntary
treatment. Patients with earlier onset of schizo-
phrenia were more likely to have involuntary treat-
ment, which may be explained by the poorer
outcome of this patient group (24).
Antipsychotics, as expected, comprised the most
frequent class of drugs for involuntary treatment
in this patient group. Olanzapine was the atypical
antipsychotic drug most frequently used, in consis-
tence with general use of antipsychotics (25). The
relatively high numbers, in involuntary treatment,
of zuclopenthixol, olanzapine and haloperidol may
reflect the fact that parenteral route of administra-
tion is available for these drugs.
For olanzapine 44% and quetiapine, 27% of the
patients received higher than recommended dos-
ages. Such is controversial in involuntary treat-
ment where patients do not have the option to
refuse the treatment and because of the current leg-
islation. In addition, treatments including more
than one psychotropic comprised 9.1% of all treat-
ments. Evidence for beneficial effects from doses
above the recommended range, as well as from
polypharmacy, remains sparse (26). In treatment
resistant cases clozapine is a more evidence-based
Table 3. Antipsychotic drugs used in involuntary treatment
#
Mean
maximum
dose
Above
recommended
dose
Maximum
allowed
dose
Oral
Amisulpride 10 711.1 (SD = 318.0) 0 (0.0%) 1200 mg
Aripiprazole 116 23.8 (SD = 10.3) 6 (5.2%) 30 mg
Chlorprothixene 8 87.5 (SD = 44.3) 0 (0.0%) 600 mg
Clozapine 85 430.9 (SD = 246.9) 0 (0.0%) 900 mg
Flupenthixol 10 22.8 (SD = 14.8) 0 (0.0%) 40 mg
Levomepromazine 5 215.0 (SD = 230.2) 1 (20.0%) 300 mg
Haloperidol 104 17.9 (SD = 10.8) 7 (6.7%) 30 mg
Olanzapine 449 27.7 (SD = 15.6) 197 (43.9%) 20 mg
Paliperidone 10 8.3 (SD = 3.3) 0 (0.0%) 12 mg
Perphenazine 44 26.3 (SD = 13.8) 0 (0.0%) 64 mg
Quetiapine 86 754.6 (SD = 352.6) 23 (26.7%) 800 mg
Risperidone 330 5.7 (SD = 3.0) 0 (0.0%) 16 mg
Sertindole 13 15.6 (SD = 6.4) 0 (0.0%) 24 mg
Sulpiride 1 1800.0 (SD = -) 0 (0.0%) 1800 mg
Ziprasidone 54 166.1 (SD = 65.1) 11 (22.4%) 160 mg
Zuclopenthixol 226 28.8 (SD = 15.8) 19 (8.4%) 40 mg
Injection
Aripiprazole 144 15.3 (SD = 8.6) 0 (0.0%) 29.3 mg
Clozapine 2 350.0 (SD = 70.7) 0 (0.0%) 900 mg
Levomepromazine 10 11.3 (SD = 204.9) – –
Haloperidol 310 11.1 (SD = 8.1) 8 (3.1%) 30 mg
Olanzapine 503 15.7 (SD = 9.5) 35 (7.6%) 20 mg
Ziprasidone 145 34.4 (SD = 32.7) 14 (10.4%) 40 mg
Zuclopenthixol 137 16.8 (SD = 9.1) 0 (0.0%) 80 mg
Depot injection
Flupenthixol
decanoate
5 120.0 (SD = 75.8) 0 (0.0%) 200 mg/2w
Haloperidol
decanoate
47 262.2 (SD = 62.3) 30 (66.7%) 200 mg/2w
Olanzapine
pamoate
11 338.2 (SD = 53.0) 0 (0.0%) 450 mg/2w
Perfenazine
decanoate
24 180.7 (SD = 99.8) 0 (0.0%) 400 mg/2w
Risperidone
long acting
93 53.1 (SD = 17.6) 23 (26.7%) 50 mg/2w
Zuclopenthixol
acetate
87 93.3 (SD = 41.4) 1 (1.3%) 225 mg/3d
Zuclopenthixol
decanoate
86 263.9 (SD = 147.3) 5 (6.5%) 400 mg/2w
Table 4. Pharmaceutical form used for involuntary treatment with psychotropics
Main Subsidiary
# % # %
Tablets 770 43.0 42 3.1
Draught 295 16. 15 1.1
Oral disintegrating tablets 397 22.2 9 0.7
Injection 73 4.1 1200 87.5
Injection depot 234 13.1 32 2.3
Zuclopenthixol acetate 17 1.0 70 5.1
Gastric tube 6 0.3 4 0.3
Total 1792 100.0 1372 100.0
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alternative (26, 27) and a previous study has docu-
mented its feasibility, safety and effectiveness as
involuntary treatment (28). Still only 85 (4.8%)
involuntary treatments involved clozapine even
though clozapine remains the drug of choice for
treatment resistant schizophrenia, thus in most
treatment, guidelines recommended as the drug of
choice following failure of two or three antipsy-
chotic drugs (26, 29, 30).
In general, psychiatrists seem reluctant to pre-
scribe clozapine, and even more so in involuntary
treatment, considering the relative chronicity in
this group of patients (31, 32). One reason may be
fear of serious side effects, another the necessity of
haematological monitoring (33). The unavailability
of clozapine as an injectable drug also may prevent
psychiatrists from prescribing clozapine for invol-
untary treatment.
The unique effect of clozapine, including higher
level of insight into the disease and thereby longer
time to discontinuation (34), may call for prescrip-
tion of clozapine after non-response to two or
three different antipsychotics, even when invol-
untary treatment is warranted. Involuntary treat-
ment with clozapine should be practicable using a
stomach tube or having injectable clozapine
manufactured.
Several of the atypical short-acting injectable
drugs are only licensed for three consecutive days
which often led to alternation between two kinds of
injectable antipsychotics. From a pharmacological
point of view, this is inappropriate and future stud-
ies investigating the safety of injectable antipsy-
chotics beyond three days should be carried out.
Electroconvulsive therapy (ECT) comprised
almost 5% of all involuntary treatments, which is
rather high based on the sparse evidence for ECT
in patients with schizophrenia (35). Unfortunately,
indication for ECT or description of symptoms
was not available. However, some evidence exists
for treatment refractory schizophrenia, catatonic
symptoms and from acute relapse when a more
rapid improvement is desired (35, 36).
Only 13% of the involuntary treatment (main
treatment) included depot injection. In involuntary
treatment, long-acting antipsychotics have several
advantages. Depot injections every 2–4 weeks
should be less stressful for patients, objecting to
medicine, compared with daily injections or tab-
lets. Also, in general, the amount of time before
discontinuation is higher for treatment with depot
injections compared with oral treatment (37).
Thirdly, avoiding parenteral depot medication by
coercion is not possible, because oral medications
patients can easily cheat (38). On the downside, the
palettes of parenteral atypical antipsychotics
depots remain limited, but the availability may
increase in the future.
More studies are warranted to investigate the
effects of involuntary treatment with depot injec-
tions, and legislators should be aware of the poten-
tial effect of such interventions on compliance and
course.
This study should be interpreted within its limi-
tations. A large portion of the protocols was not
sufficiently completed or blank, which could be
due to lack of reporting. Regarding involuntary
somatic treatment, data and description often were
wide and non-specific (e.g. ‘treatment of physical
disease’) containing no information on drug or
dosage. Indications for psychotropics were not
available, which frequently makes it impossible to
distinguish, for instance, whether antiepileptics are
used for seizure control or mood stabilizing.
Unfortunately, drugs used for rapid tranquiliza-
tion were not specified in the protocol.
Comparing this study to other studies is
restricted because of the lack of existing literature
within this field and international differences in
mental health acts and procedures of involuntary
treatment. Most studies have investigated the
effects of involuntary community treatment, which
was not allowed during in Denmark during the
study period (39). One study investigating the
short-term effect of involuntary treatment during
hospitalization revealed that no differences at time
of discharge as regards to psychopathology and
level of functioning (40). Since lack of insight is an
important risk factor for non-adherence and invol-
untary admission, psychiatrists should aim for
remission of psychotic symptoms, try to involve
the patient in decision making and provide psycho-
education to increase the patient’s level of insight
into the disease and thereby increase the likelihood
of continuing treatment after discharge (41).
A Cochrane study concluded that compulsory
community treatment did not result in any signifi-
cant difference in service use, social functioning or
quality of life patients sentenced to involuntary
community treatment compared with standard
care, although they were less likely to be involved
in serious crime (39). Other studies have concluded
that involuntary out-patient treatment is effective
and can easily be managed with rarely use of physi-
cal force (42). Our study only aimed to describe
current use of involuntary treatment among
schizophrenia inpatients and thus further investi-
gation of the long-term effects, both as regards to
compliance and to the psychological effects is
beyond its scope.
In conclusion, 16.5% of all psychiatric admitted
patients with schizophrenia during a 7-year study
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period underwent involuntary treatment. More
studies investigating involuntary treatment is war-
ranted to obtain knowledge on feasibility of invol-
untary treatment and the outcome of such
treatment.
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